Automating The Drive Towards Personalised Medicine By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed, as well… Read More
Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Although a high… Read More
The Current Status of Non-Biopharma Drug Discovery By Dr John Comley Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides… Read More
Rules For Drug Discovery: Can simple property criteria help you to find a drug? By Dr Matthew Segall The years since the publication of Lipinski’s Rule of Five (Ro5) (1) in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by… Read More
How Digital Innovation and Collaboration Is Driving a Global Demand for Effective Reporting in Research Funding By Frances Buck The UK, Europe and the United States are world leaders in research and innovation, with their researchers making vast contributions to global knowledge. They have world-leading universities, research institutes and scientific… Read More
Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion… Read More
Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of appropriate knowledge… Read More
Digital PCR (dPCR) and Real-Time PCR (qPCR): A time and place for each By Dr George Karlin-Neumann and Dr Rachel Scott When it comes to DNA research, scientists often find themselves weighing digital PCR (dPCR) against the more established quantitative real-time PCR (qPCR). Which technique is better to use? The… Read More
By Dr John Comley 3D cell culture has the potential to deliver higher quality culture information that is more representative of tissue morphology and predictive of drug responses in vivo. Three years ago we concluded in DDW that 3D cell culture was still open to major improvements, so what has… Read More
Stem Cell Banking In Support of Drug Discovery By Dr Thomas J Novak, Dr Uta Grieshammer, Dr Michael Yaffe and Dr Steve Madore The discovery by Yamanaka and Thomson in 2007 that human somatic cells can be reprogrammed to a pluripotent state (ie, induced pluripotent stem cells, iPSCs) has revolutionised… Read More
Large-Scale Expansion of Stem Cells For Therapy and Screening By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and differentiate makes… Read More
The Drug Repositioning Revolution: Rescuing & Repurposing Drugs By Dr Monika Green and Dr Kate Hudson-Farmer Cost containment and improving ways of treating people are key drivers for healthcare systems. Unfortunately, these do not often go hand in hand. Finding novel therapeutics with enhanced efficacy is both time consuming and… Read More
Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays By Dr Nikolai Schwabe and Katherine Catchpole The progression from health to disease is marked by significant biological changes within an individual (1). Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after… Read More
Gene Editing: Re-writing Genomes With Targetable Nucleases By Dr Dana Carroll We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites, introduction of designed… Read More
Fluorescence Lifetime Assays By Dr Graham Cotton, Dr Wayne Bowen, Dr Robert Grundy and Dr Ulrich Hassiepen The benefits of fluorescence lifetime-based technologies (FLT) have been highlighted for more than a decade but thus far they have failed to gain widespread acceptance. Significant improvements in assay reagents and availability of… Read More
By Dr Alejandra Solache, Robert Brockett, Trinette Chuang, Dr Robin Clark, Rey Dimagiba, Dr April Fisher, Dr Wayne Speckmann and Dr Chun Yang Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting… Read More